Shares in Ballymore Resources Ltd (ASX: BMR) are flinging higher today and now trade 9% in the green at 18 cents apiece.

At one point today, Ballymore shares were rallying as high as 50% before receding the line back down to current levels.

Why is the Ballymore share price soaring today?

The company announced it has received gold assay results for the initial drilling program at the Seventy Mile Mount prospect.

The site is located within the Ravenswood Project area, itself situated in the Charters Towers Province in northeast Queensland.

According to Ballymore, the findings demonstrate the potential for Seventy Mile Mount to “host a significant breccia-hosted gold deposit similar in style to Mount Leyshon (3.8 Moz Au) and Mount Wright (1.0 Moz Au)”.

Results also show significant new intersections of 40m at 1.06 g/t Au from 47m (including 3m at 9.38 g/t Au) in and 15m at 0.55 g/t Au from 76m (including 5m at 1.44 g/t Au) in two separate holes.

“Matched with historic drilling, these results support the interpretation that Seventy Mile Mount is a zoned system with grade improving with depth”, the company remarked.

Management commentary

Speaking on the results, Ballymore Technical Director, David A-Izzeddin said:

The Seventy Mile Mount breccia target has a lot of similarities to major breccia hosted gold deposits in the region and these recent holes are the first completed in the area since 2004. These holes targeted a previously unrecognised breccia zone with similarities to the higher grade breccia zones present at Mount Leyshon and Mount Wright, both major gold producers in the local region in the past 30 years.

This initial drilling program was designed to test the continuity of the gold from the eastern margins to the west, and has proven successful in intersecting shallow, ore grade mineralisation 200m west of the zone of best historic drill results. Initial assessment of the breccias and geochemical data suggests that we are at the top of a zoned system similar to Mount Wright. The only previous deep drilling at Seventy Mile Mount was completed on the eastern margin of this breccia zone and these results support the interpretation that grades will improve with depth.

What’s next for this ASX mining share?

Ballymore says that it will now receive assay results for Matthews Pinnacle CEI drill hole and then commence drilling at Ruddygore mine in March 2022.

It also aims to design a Stage 2 drilling program for Seventy Mile Mount, complete soil sampling and mapping program at its Dittmer Project and also mapping of the Day Dawn and Tea Tree prospects located at Ravenswood.

Since listing in September last year, Ballymore shares have collapsed 10%, however are up 3% this year to date, and another 12% in the green over the past week.

The post This junior ASX mining share just leapt 50%. Here’s why appeared first on The Motley Fool Australia.

More reading

• Brokers name 3 ASX shares to buy today
• Here’s why the Starpharma (ASX:SPL) share price is tumbling 8% today
• The NAB (ASX:NAB) share price has only gained $3 in 12 years. Have the dividends been worth it?
• Mission possible: Why this ASX mining share is surging 17% today
• QBE (ASX:QBE) share price backtracks as CEO realigns group’s strategy

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/GY7BWfb

Shares in Starpharma Holdings Limited (ASX: SPH) are on the move today after the company released a market sensitive announcement. At the time of writing, the Starpharma share price is down 7.87% at 82 cents.

The announcement relates to a story in today’s The Age regarding the company’s Viraleze nasal spray.

Viraleze is an antiviral nasal spray used overseas for the treatment of Covid-19. It is registered for sale in Europe, Vietnam, India, Saudi Arabia, and New Zealand, and “available outside Australia in certain markets online”, according to the company.

Starpharma is awaiting the outcome of an application for approval from the Therapeutic Goods Administration (TGA) to sell the product in Australia.

What did the media article say?

The article states that the TGA “believes the company has applied for the wrong therapeutic goods category”.

In the article, a TGA spokeswoman is quoted as saying:

The TGA can confirm that Starpharma submitted an application for Viraleze for inclusion in the Australian register of Therapeutic Goods as a medical device. According to the Therapeutic Goods Act 1989 and based on information provided by Starpharma to the TGA and information they have published in the public domain, Viraleze would be a medicine, not a medical device.

The TGA has discussed the differences between a medicine and medical device with Starpharma verbally and in writing on several occasions, as recently as mid-January 2022. To date, Starpharma has not sought advice from the medicines authorisation branch of the TGA nor have they submitted an application for this product to be included in the [register] as a medicine.

What is Starpharma’s response?

In its release today, Starpharma affirmed it has submitted an application to the TGA for Viraleze as a medical device. It said this is in line with other countries, and that the regulatory process “is ongoing”.

Starpharma said:

Starpharma does not normally comment on ongoing regulatory processes and was not anticipating the TGA to make public comment, given we are currently awaiting a response from the TGA, having provided additional information as recently as last week, including information related to the nasal spray mechanism of action and the appropriateness of its classification as a medical device.

Starpharma’s submission for this product as a medical device is consistent with multiple other nasal sprays with antiviral indications that are registered by the TGA as medical devices and have been marketed in Australia for several years.

This is important because, as the company notes, Viraleze is already registered as a medical device in Europe and elsewhere, but also under the Therapeutic Goods Act 1989.

Let’s not forget that Starpharma and the TGA have had a fairly colourful past. Last year, the TGA fined Starpharma more than $90,000 for promoting Viraleze on YouTube despite it not yet having approval.

Starpharma stated further:

We appreciate the TGA’s important role in regulating the supply of therapeutic goods in Australia and look forward to working with the TGA to achieve registration of the nasal spray in Australia to make the product available to Australian consumers.

It remains to be seen what the TGA will decide regarding Viraleze. The application is still being evaluated.

Starpharma share price snapshot

In the past 12 months, the Starpharma share price has collapsed by 60%. It is trailing the broader S&P/ASX 200 Health Care Index (ASX: XHJ) in 2022. The index is down 15% while the Starpharma share price has lost 37% year to date.

The post Here’s why the Starpharma (ASX:SPL) share price is tumbling 8% today appeared first on The Motley Fool Australia.

More reading

• Starpharma (ASX:SPL) share price lifts on Omicron study results
• Not enough: Starpharma (ASX:SPH) share price plunges despite 200% revenue growth

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/gZMAyUo

As a big four bank share on the S&P/ASX 200 Index (ASX: XJO), the National Australia Bank Ltd. (ASX: NAB) share price arguably casts a long shadow on our share market. It’s one of the largest companies in Australia, and also one of the most well known. This has been accentuated in recent years as NAB has grown in size. A few years ago, this bank was the baby of the big four. Today, it is the ASX’s second-largest bank, behind Commonwealth Bank of Australia (ASX: CBA), of course. 

And NAB shares have proven to be a rewarding investment in recent times too. As it currently stands, the NAB share price has given investors a return of 9.35% over the past 12 months. That’s more than double the return of the broader ASX 200.

But this recent run masks a longer-term performance that isn’t so rosy. If we look at the NAB share price over the past 5 years, we can see that it has fallen by more than 13.5% over this period.

And even stretching back to 12 years, NAB shares have only seen roughly $3 added to their price.

But, as any bank investor would know, part of the appeal of an ASX bank like NAB are the dividends. And NAB has certainly paid out some hefty dividends over this period. So let’s see if those payments have added meaningfully to NAB’s returns. 

Do NAB’s dividends make the past 12 years worthwhile?

Ok, so back in early March 2010, NAB shares were going for roughly $25.63. Say if an investor invested $10,000 in NAB shares back then, it would have netted them 390 NAB shares with some change. 

Today, those 390 NAB shares would be worth $11,161.80 at NAB’s present share price of $28.62. That’s a rather anaemic capital return of 11.62% over 12 years. On that alone, you would probably have been better off having the cash stored in a NAB savings account instead. That doesn’t include any share buybacks, capital initiatives, or NAB’s dealings with the old Clydesdale Bank, just for simplicity. 

But let’s get to the dividends. So Since March 2010, NAB has forked out $20.37 in dividends per share. That’s including both of NAB’s 2021 dividend payments.

For an investor owning 390 NAB shares, that would amount to $7,944.30 in dividend income. Again, we won’t include the value of franking for simplicity’s sake. 

So if we add that $7,944.30 in dividend income to NAB’s capital return of $1,161.80, we can conclude that that $10,000 invested would have netted an investor a total of $9,106.10. Or $19,106.10 including our principle.

That means NAB shares have returned 91.06% over those 12 years. That works out to be an annual rate of return of 5.54% per annum. You can probably throw on a couple of percentage points to that to account for the franking if you’d like. 

Going off of how an ASX 200 ETF like the iShares Core S&P/ASX 200 ETF (ASX: IOZ) has given its investors an average return of 9.29% over the past 10 years, it’s unlikely that NAB has been a market beater over the past 12 years. But at least those returns beat out a savings account now.

At the current NAB share price, this ASX 200 bank has a NAB has forked out $20.37 in dividends per share of $92.48 billion, with a dividend yield of 4.44%. 

The post The NAB (ASX:NAB) share price has only gained $3 in 12 years. Have the dividends been worth it? appeared first on The Motley Fool Australia.

More reading

• Why brokers rate these ASX 200 dividend shares as buys
• Australia’s newest tech unicorn, Zeller, is taking on the ASX banks. Here’s how
• Why did the NAB (ASX:NAB) share price leap 7% in February?
• ‘A lot of headroom to grow’: Is 2022 the year ASX investors turn to ESG shares?
• Own NAB (ASX:NAB) shares? Here’s why the bank has been ruffling some customer feathers

Motley Fool contributor Sebastian Bowen owns National Australia Bank Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/I5qoThm

The Minerals 260 Ltd (ASX: MI6) share price is roaring today and is now 17.02% higher at 55 cents. At one point today, Minerals 260 shares were trading as high as 59 cents apiece, before recoursing back to current levels.

Investors are responding well to an announcement out of the company’s camp today regarding its 100%-owned Moora project, located approximately 150km northeast of Perth.

What did Minerals 260 announce?

The Minerals 260 share price is surging after the company advised it has received assays for a further nine holes from the recently completed drilling program at the Moora site. The findings confirm a wide copper-gold zone at the project.

According to Minerals, the Moora project forms part of a contiguous, 1,000km2 land position that also includes the Koojan venture with Lachlan Star Ltd (ASX: LSA) next door.

Earlier in January, Minerals 260 completed a 37-hole diamond core and reverse circulation (RC) drilling program for a total of 6,196 metres on various anomalies at the site.

Results from the Mynt prospect show mineralisation was intersected at 24m at 1.9% copper and 0.7 grams of gold per tonne from 99-123m.

“[The] mineralisation hosted by a quartz-veined zone with disseminated to semi-massive chalcopyrite and pyrrhotite,” Minerals 260 said.

Minerals 260 also notes the presence of mineralisation with “significant geochemical and geophysical anomalies” indicates the potential for a large sulphide-related system.

Assays received for a further eight drill holes at another prospect located on the site confirm the continuity of gold mineralisation. This has now been intersected on five sections over 400 metres of strike in all directions.

Management commentary

Speaking on the news fuelling the Minerals 260 share price today, managing director David Richards said:

The recent drilling and geophysical results continue to highlight the potential for large mineralising systems at Moora and Koojan. While we still have a lot of assay and other data to review and analyse, we are developing a clearer understanding of the priority areas for follow-up drilling.

One is clearly the exciting new copper-gold zone delineated at the Mynt prospect, where geophysics indicates potential for a significant mineralised system. The other is at Angepena, where we have now delineated significant gold mineralisation over an extensive area.

Minerals 260 share price snapshot

Since listing last year the Minerals 260 share price has gained 12%. It is also up 5.6% this year to date.

During the past month, its shares are up 1.8% and they have exploded by almost 32% over the past week.

The post Mission possible: Why this ASX mining share is surging 17% today appeared first on The Motley Fool Australia.

More reading

• QBE (ASX:QBE) share price backtracks as CEO realigns group’s strategy
• ASX 200 (ASX:XJO) midday update: Block, Zip tumble, QBE’s asset sale
• Why is the ANZ (ASX:ANZ) share price getting battered more than the other banks this week?
• 3 ASX shares to cash in from the energy crisis: expert
• The CSL (ASX:CSL) share price is falling today, but here’s what investors can look forward to next week

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/REUKOdF

The QBE Insurance Group Ltd (ASX: QBE) share price is looking to finish Friday’s trading session in the red. This comes after the insurance giant provided a market release in relation to a divestment of its United States-based business.

At the time of writing, QBE shares are down 1.28% to $10.77 apiece. In comparison, the S&P/ASX 200 Index (ASX: XJO) is down 0.54% to 7,112.6 points.

Let’s take a closer look at what the company updated the ASX with today.

What did QBE announce?

In today’s statement, QBE advised it has entered into an agreement to sell its Westwood Insurance Agency to Baldwin Risk Partners (NASDAQ: BRP).

Based in California, Westwood is a leading full service personal lines agency, specialising in builder sourced homeowners’ insurance.

Under the deal, QBE will receive a total consideration of $375 million, subject to regulatory approval.

The transaction is expected to increase the group’s Australian Prudential Regulation Authority (APRA) prescribed capital amount (PCA) multiple by around 0.05x.

The capital adequacy prudential standards require an insurance company to maintain enough capital against any risks associated with its activities. It is also a requirement that the insurer make certain public disclosures about its capital adequacy position.

QBE group CEO, Andrew Horton commented:

QBE’s strategy in North America is focused on building its Commercial, Specialty and Crop insurance portfolios. Whilst an attractive franchise, the Westwood business does not align with this strategy, and following this transaction QBE will no longer own any agency businesses in North America.

The sale is anticipated to be finalised by 1 May 2022.

In addition to the announcement, QBE touched on the recent flooding in Queensland and New South Wales.

Since the heavy rains swept a number of regions, around 3000 claims were lodged by customers. While a majority of those were personal lines, QBE is anticipating further claims in the coming weeks.

Management noted that it is still too early to assess the financial impact of the weather-related event.

However, the group has a maximum event retention of $125 million for non-peak events in the Australia Pacific Division. QBE’s FY22 catastrophe allowance is $962 million including a first-quarter allowance of $248 million.

About the QBE share price

Over the past 12 months, QBE shares have been somewhat volatile, moving in peaks and troughs throughout the period.

While its shares have gained around 13% since this time last year, it’s still heavily down from pre-pandemic levels. In early 2020, the QBE share price was swapping hands for as high as $15.19, before plummeting to record lows.

Based on today’s price, QBE commands a market capitalisation of roughly $15.92 billion, with more than 1.48 billion shares outstanding.

The post QBE (ASX:QBE) share price backtracks as CEO realigns group’s strategy appeared first on The Motley Fool Australia.

More reading

• ASX 200 (ASX:XJO) midday update: Block, Zip tumble, QBE’s asset sale
• ‘$2 billion cost’: How are the floods impacting ASX 200 insurance shares this week?
• 4 ASX shares that love rising interest rates: report
• Should you buy QBE (ASX:QBE) shares as an inflation hedge?
• 3 ASX 200 value shares to buy for higher inflation: fundie

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/yJCQNen

At lunch on Friday, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week deep in the red. The benchmark index is currently down 1.7% to 7,030.8 points.

Here’s what is happening on the ASX 200 today:

Tech shares tumble

The tech sector is weighing heavily on the ASX 200 on Friday. At the time of writing, the S&P/ASX All Technology Index is down a sizeable 3.5% due to heavy declines from the likes of Block Inc (ASX: SQ2) and Zip Co Ltd (ASX: Z1P). This follows a poor night of trade on the tech-focused Nasdaq index and futures contracts pointing to more of the same tonight.

CSL lower despite acquisition update

The CSL Limited (ASX: CSL) share price is falling on Friday despite the release of an update out of the biotherapeutics giant. That update reveals that its proposed acquisition of Vifor Pharma for ~$17 billion has taken a step closer to completion. This follows news that 74% of Vifor shares have been tendered following CSL’s offer. If everything else goes to plan, management expects the transaction to complete in mid-2022.

QBE asset sale

QBE Insurance Group Ltd (ASX: QBE) has announced a deal to sell its Westwood Insurance Agency business in the United States. The insurance giant has entered into an agreement that will see the North American agency sold to Baldwin Risk Partners for $375 million. Westwood is a leading national full service personal lines agency, specialising in builder sourced homeowners’ insurance.

Best and worst ASX 200 performers

The best performer on the ASX 200 on Friday has been the Incitec Pivot Ltd (ASX: IPL) share price with a modest 1% gain. This appears to be due to the prospect of higher urea/ammonia prices due to the Russia-Ukraine crisis. The worst performer has been the Zip share price with an 11% decline amid weakness in the tech sector.

The post ASX 200 (ASX:XJO) midday update: Block, Zip tumble, QBE’s asset sale appeared first on The Motley Fool Australia.

More reading

• The CSL (ASX:CSL) share price is falling today, but here’s what investors can look forward to next week
• The 14% discount offered on the Zip (ASX:Z1P) share purchase plan has now vanished. What now for investors?
• Think you have the ‘right skills’ for investing in ASX shares? Read this
• CSL (ASX:CSL) share price on watch following Vifor Pharma acquisition update
• 5 things to watch on the ASX 200 on Friday

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended Block, Inc., CSL Ltd., and ZIPCOLTD FPO. The Motley Fool Australia owns and has recommended Block, Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/FC6zwls

Shares in Australia and New Zealand Banking Group Ltd (ASX: ANZ) are falling today and now sit at $25.16 apiece.

The banking giant has been underperforming the other majors and is now 4.8% in the red this week.

ANZ shares are now down 10% in 2022 compared to a loss of 8% for the S&P/ASX 200 Financials Index (ASX: XFJ) and 9% for the S&P 500 index (NYSE: SPX).

ANZ is the worst performer among the big four banks this year. The second worst performer is Commonwealth Bank of Australia (ASX: CBA) down 8.7% year to date. The best performer is Westpac Banking Corp (ASX: WBC), up 1.5%.

Why is the ANZ share price tracking lower?

Market pundits have overlooked ANZ shares in favour of the other banks this year. Although, investors should note that ANZ is one of the only banks not to have reported its half-yearly accounts.

ASX banking shares took off in January amid talks of a shifting interest rates regime and hot-running inflation.

Now, with economic sanctions placed on some Eastern European banks due to the Russian invasion of Ukraine, there’s nervousness in the global banking sector. This is reflected in the price movements of banking indices around the world.

Benchmark’s tracking shows each of the Australian, American and European (shown by the German banking index) indexes falling into the red, as seen below.

In fact, the trend is quite clear when we look at the number of S&P 500 financial stocks that are above their 200-day moving average versus the number above their 50-day moving average.

For reference, if a stock is trading above either of these two averages, it tends to be considered in an uptrend.

Both have taken a big step backwards in the last month or so, however, the number of S&P 500 financials stocks trading above the 200-day is down 40% whereas the number below their 10-week average is 72%.

Check out the volatility of these numbers on the chart below to see how things have progressed for ASX financials over the past 12 months.

The market is continuing to digest the wave of macro-economic activity that’s shaking up the financial system. This is most certainly impacting shares like ANZ.

Not everyone is as downbeat on ANZ

Analysts at JP Morgan and Goldman Sachs are both bullish on the bank and recommend it as a buy right now. Both brokers like ANZ’s prospects for 2022. JP Morgan increased its net interest margin (NIM) forecasts by 3% for FY23/24 to reflect rate hikes this year.

Goldman thinks the bank is making good progress on its mortgage business to become more competitive. It has a target of almost $31 for the ANZ share price. JP Morgan values ANZ at a price of $30.50 per share. Both suggest more than 20% upside at the time of writing.

As The Motley Fool reported yesterday, about 60% of brokers have ANZ as a buy right now with a consensus price target of $29.13.

The post Why is the ANZ (ASX:ANZ) share price getting battered more than the other banks this week? appeared first on The Motley Fool Australia.

More reading

• Australia’s newest tech unicorn, Zeller, is taking on the ASX banks. Here’s how
• Can this ASX 200 bank share flame 20% higher?
• Top brokers name 3 ASX shares to buy today
• Why did the ANZ (ASX:ANZ) share price lag the other banks in February
• Own ANZ shares? Here’s the bank’s latest move to ‘better prepare for future growth’

JPMorgan Chase is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended Goldman Sachs. The Motley Fool Australia has recommended Westpac Banking Corporation. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/rTCsaoK

Post-COVID economic recovery and now the war in Ukraine have prompted experts to warn that energy prices will climb.

Already a new gas pipe from Russia to Germany has been halted, placing higher demand for energy from other parts of the world.

According to Datt Capital chief investment officer Emanuel Datt, there are numerous voluntary boycotts of Russian products in addition to the official sanctions.

“For instance, a commodity trading house may struggle to obtain the requisite insurance and finance to cover the purchase and transport of a shipment of Russian-origin commodities,” he said.

“As such, almost overnight, we have seen an enormous uplift in demand for commodities of non-Russian origin to fill this sudden supply gap.”

Datt cited Newcastle thermal coal futures climbing 46% overnight to close at US$446 per tonne.

“This is in contrast to prices of ~US$190 a tonne only 2 months ago,” he said.

“The price of crude oil has exploded with the Brent benchmark currently trading at ~US$116 a barrel vs US$77 a barrel 2 months ago.”

All this has led to ideal conditions for investors to pounce on certain Australian companies that are set to benefit, according to Datt.

He specifically named 3 ASX shares in the energy sector “worth keeping a close eye on”:

Selling coal at 3 times the price

According to Datt, Russian coal supplies about 15% to 20% of Japanese and Korean demand.

As an exporter to those countries, Whitehaven Coal Ltd (ASX: WHC) can take advantage.

“Whitehaven’s customers will likely be willing to increase purchase volumes from Whitehaven at higher prices than has been traditionally achievable.”

Just sheer mathematics is on Whitehaven’s side. 

In the last half-yearly results, the company reported an average realised price of $211 per tonne.

“With current spot prices over $600 a tonne, we believe that Whitehaven is well equipped to capture these higher prices at greater production volumes than last quarter.”

Datt also likes the $400 million share buyback, where Whitehaven could purchase up to 10% of its own shares on-market.

“The debt-free balance sheet and high-quality assets make this a compelling value proposition at a market cap of less than$4 billion.”

Whitehaven shares have rocketed more than 43% for the year so far.

Gas and oil ready to be snapped up

Datt noted that Woodside Petroleum Limited (ASX: WPL) would now become “a global top 10 oil and gas company” after absorbing BHP Group Ltd (ASX: BHP)’s petroleum arm.

The business’ last reported realised prices for liquified natural gas and oil were US$28/MMBtu and US$80/bbl respectively, which are considerably below current market prices.

“We see Woodside as possessing strong leverage to higher O&G prices going forward whilst also paying an attractive dividend yield.”

Indeed, Woodside currently pays out a dividend yield of just over 6%.

And finally, Datt likes the look of Santos Ltd (ASX: STO).

“Last calendar year, Santos managed to capture realised prices of US$9/MMBtu for LNG and US$76/bbl,” he said. 

“Accordingly, there is a strong opportunity to capture materially higher prices given the current market conditions.”

Datt added that the business has room for further productivity improvements.

“We also expect that Santos will reduce its stake in certain development assets, which provide the potential for future capital returns, along with its regular dividend.”

Santos shares currently yield 2.54% of dividend payouts.

The post 3 ASX shares to cash in from the energy crisis: expert appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Friday
• Here are the top 10 ASX shares today
• Here are the 3 most heavily traded ASX 200 shares this Thursday
• Aussie coal is in hot demand, and these ASX coal shares are booming
• The Woodside (ASX:WPL) share price has smashed at least 8 52-week highs in the last month. What’s next?

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/9gKzWRV

It hasn’t been a very pleasant day for the CSL Limited (ASX: CSL) share price so far today. Or the S&P/ASX 200 Index (ASX: XJO) for that matter. At the time of writing, the ASX 200 has fallen by 1.36% and is back under 7,100 points. As it currently stands, CSL shares are trading at $254.83 each, down 1.04% so far today.

it appears the announcement that CSL made last night hasn’t been enough to buck the trend of the broader market. Although, it’s worth saying that perhaps it has been enough to give the healthcare giant a slight edge over the ASX 200.

As my Fool colleague James covered this morning, CSL has announced an update regarding its major acquisition plans. Back in December last year, CSL announced it was intending to acquire the Swiss biotech company Vifor Pharma for US$12.3 billion in cash. Well, we got an update on this proposed buyout after market close yesterday.

CSL revealed that 74% of Vifor shares have been tendered as part of its public tender offer. Originally, the deal had an 80% target. However, CSL has decided to waive this requirement and will be pressing ahead with the deal. It still plans to have the acquisition cross the finish line by mid-2022.

So perhaps this development is having an impact on the CSL share price so far this Friday.

CSL shares to pay out next month

But there is also a big event for CSL coming up next week.

Monday will see this healthcare share trade ex-dividend for its upcoming interim dividend payment. This dividend was announced when the company delivered its half-year earnings results last month. The dividend investors are to receive will be a US$1.04 payment, which will be worth approximately A$1.42 per share going off current exchange rates. The raw US$1.04 payment is flat on last year’s interim dividend. It will come unfranked.

So today is effectively the last day that investors can buy CSL shares if they want to receive this dividend. Come Monday, any new investors will be ineligible, and as such, the value of this dividend will leave the CSL share price. So don’t be surprised if we see a share price fall for CSL on Monday. But investors will have to wait until April 6 to see this dividend hit their bank accounts. Something to look forward to.

At the current CSL share price, this ASX 200 healthcare share has a market capitalisation of $123.27 billion, with a dividend yield of 1.02%

The post The CSL (ASX:CSL) share price is falling today, but here’s what investors can look forward to next week appeared first on The Motley Fool Australia.

More reading

• Think you have the ‘right skills’ for investing in ASX shares? Read this
• CSL (ASX:CSL) share price on watch following Vifor Pharma acquisition update
• 5 things to watch on the ASX 200 on Friday
• Here are the top 10 ASX shares today
• ASX 200 (ASX:XJO) midday update: Corp Travel Management’s ACCC boost, Zip downgraded

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/gAJYsex

It’s a case of another day, another decline for the Zip Co Ltd (ASX: Z1P) share price on Friday.

In morning trade, the buy now pay later (BNPL) provider’s shares are down 8% to a new 52-week low of $1.72.

This means that the Zip share price is now down over 43% in the space of a month and 22% since announcing its capital raising.

What does this mean for the share purchase plan?

Earlier this week Zip launched a $198.7 million capital raising. This comprises a (now complete) $148.7 million institutional placement at $1.90 per new share and a share purchase plan aiming to raise up to $50 million.

Proceeds from the placement and share purchase plan will be used to help Zip strengthen its balance sheet and position it for sustainable growth by providing more capital runway to execute on the potential synergies from the proposed acquisition of Sezzle Inc (ASX: SZL).

But with the Zip share price now trading 9.5% below its placement price, investors may be wondering what this means for the share purchase plan.

When announcing the share purchase plan, Zip advised that eligible shareholders have the opportunity to apply for up to $30,000 of new Zip shares at the lower of the placement price or a 2% discount to the five-day volume weighted average price of Zip shares up to and including the closing date of the plan. This is expected to be 1 April 2022.

Based on the current Zip share price, the latter is looking to be the more likely price for the share purchase plan. However, this may not be overly popular with shareholders given the minimal discount compared to the 14% discount that institutional investors received. This may ultimately lead to Zip’s share purchase plan falling short of its target.

The post The 14% discount offered on the Zip (ASX:Z1P) share purchase plan has now vanished. What now for investors? appeared first on The Motley Fool Australia.

More reading

• 2 ASX 200 financial shares that hit 52-week lows on Thursday
• Top brokers name 3 ASX shares to sell today
• Why Coles, Dusk, Monadelphous, and Zip shares are dropping today
• Zip (ASX:Z1P) shares have tumbled 14% since the merger news. Top brokers offer possible reasons why
• ASX 200 (ASX:XJO) midday update: Corp Travel Management’s ACCC boost, Zip downgraded

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended ZIPCOLTD FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/rNoSxsp